Literature DB >> 24529328

Evidence that gastric pit dysplasia-like atypia is a neoplastic precursor lesion.

Agoston T Agoston1, Robert D Odze2.   

Abstract

Most gastric cancers develop via an intestinal metaplasia (IM)-dysplasia-carcinogenic pathway. We have noted that some patients with chronic gastritis have dysplasia-like atypia (DLA) limited to the pit epithelium but without involvement of the surface epithelium. We performed this study to determine the clinical and biological characteristics and outcome of DLA, to gain insight into its role in the pathogenesis of gastric cancer. The study consisted of 102 consecutive patients with resected gastric cancer, a separate cohort of patients (n = 166) with chronic gastritis and IM in their index gastric biopsies, and 44 controls. All specimens were evaluated for clinical and pathologic features of the cancer (in the resection cohort) and background mucosa. Of 102 patients with gastric cancer, 50 (49%) had DLA in areas of mucosa adjacent to or near either conventional dysplasia or cancer. This value was significantly higher than controls (DLA 6.8%; P < .0001). Gastric cancer patients with DLA showed a significantly higher age at presentation; intestinal-type adenocarcinoma; low-grade differentiation; stage 1 tumors; and a higher rate of chronic gastritis, IM, atrophy, and conventional dysplasia in the background mucosa compared to patients without DLA. DLA showed intestinal-type differentiation, and a higher Ki-67 rate and MUC6 positivity compared with IM. Of the 166 patients with biopsies, DLA was identified in 24 (14%). Upon follow-up, 38% of positive cases showed persistent DLA, whereas 25% progressed to conventional low-grade dysplasia. Based on these results, we conclude that DLA represents an important precursor lesion in gastric carcinogenesis and supports its interpretation as a neoplastic lesion.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic gastritis; Intestinal metaplasia; Ki-67; MUC; p53

Mesh:

Substances:

Year:  2013        PMID: 24529328     DOI: 10.1016/j.humpath.2013.10.032

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

2.  Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa.

Authors:  Katherine M Riera; Bogun Jang; Jimin Min; Joseph T Roland; Qing Yang; William T Fesmire; Sophie Camilleri-Broet; Lorenzo Ferri; Woo H Kim; Eunyoung Choi; James R Goldenring
Journal:  J Pathol       Date:  2020-06-15       Impact factor: 7.996

3.  Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances.

Authors:  Yongfu Shao; Huilin Chen; Xiaoming Jiang; Shengcan Chen; Peifei Li; Meng Ye; Qier Li; Weiliang Sun; Junming Guo
Journal:  Tumour Biol       Date:  2014-06-25

Review 4.  DNA Methylation as Surrogate Marker For Gastric Cancer.

Authors:  Jung-Hwan Oh; Sung-Hoon Jung; Seung-Jin Hong; Mun-Gan Rhyu
Journal:  J Cancer Prev       Date:  2015-09

5.  Negative pathology after endoscopic resection of gastric epithelial neoplasms: importance of pit dysplasia.

Authors:  Joon Hyung Jhi; Gwang Ha Kim; Ahrong Kim; Young-Geum Kim; Cheong Su Hwang; Sojeong Lee; Bong Eun Lee; Geun Am Song; Do Youn Park
Journal:  Korean J Intern Med       Date:  2017-01-20       Impact factor: 2.884

6.  Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population.

Authors:  Huan Song; Isabella Guncha Ekheden; Zongli Zheng; Jan Ericsson; Olof Nyrén; Weimin Ye
Journal:  BMJ       Date:  2015-07-27

7.  LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer.

Authors:  Yongfu Shao; Meng Ye; Qier Li; Weiliang Sun; Guoliang Ye; Xinjun Zhang; Yunben Yang; Bingxiu Xiao; Junming Guo
Journal:  Oncotarget       Date:  2016-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.